The pLKO.1 vector plasmid was used as a negative control
Although the ROS contents in serum after APP treatment also increased significantly, the multiplicity of change was significantly smaller than that of APP-treated saline
Its dose-fussy on top of that
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
The difference between a dose that is 10% too high and one that is 10% too low might come down to which syringe you selected
Further exploration is needed to understand the regulation of mitochondrial iron content and the interaction among MTFT, Fe-S cluster, and heme [78, 84]
